Comparative Pharmacology
Head-to-head clinical analysis: K 8 versus KLOR CON M20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K 8 versus KLOR CON M20.
K+8 vs KLOR-CON M20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replenishment; corrects hypokalemia by increasing extracellular potassium concentration, restoring membrane potential and cardiac conduction.
Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of acid-base balance. Potassium replacement therapy corrects hypokalemia.
40-80 mEq intravenously per day, infusion rate not exceeding 10 mEq/hour; or 20-40 mEq orally 2-4 times daily.
20 mEq potassium chloride orally once daily, adjusted based on serum potassium levels and patient response. Maximum rate of administration: 20 mEq per hour if intravenous; oral doses divided if >20 mEq per dose.
None Documented
None Documented
Terminal elimination half-life ~2-4 hours (shorter with valproate coadministration, prolonged with renal impairment).
The terminal elimination half-life of potassium is approximately 8-12 hours in healthy individuals, but is prolonged in renal impairment.
Primarily renal: >90% excreted unchanged by kidneys. Minor fecal (<5%) and negligible biliary elimination.
Potassium is primarily excreted renally (approximately 90%) as potassium ion in urine. A small amount is excreted in feces (about 10%).
Category C
Category C
Potassium Supplement
Potassium Supplement